NRX Pharmaceuticals
NRXP
5 hedge funds and large institutions have $2.16M invested in NRX Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.
0.81% less ownership
Funds ownership: 1.56% → 0.74% (-0.81%)
17% less funds holding
Funds holding: 6 → 5 (-1)
29% less capital invested
Capital invested by funds: $3.06M → $2.16M (-$901K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$721K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bluefin Capital Management
New York
|
-$946K |
| 2 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$897K |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$743K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.98K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MF
1
Magnetar Financial
Evanston,
Illinois
| $1.25M | -$743K | -6,900 | -37% |
|
|
GCL
2
Glazer Capital LLC
New York
| $718K | +$721K | +6,698 | New |
|
|
YCM
3
Yakira Capital Management
Westport,
Connecticut
| $176K | – | – | – |
|
|
BCM
4
Bluefin Capital Management
New York
| $13K | -$946K | -8,790 | Closed |
|
|
5
UBS Group
Zurich,
Switzerland
| $5K | -$3.98K | -37 | -45% |
|
6
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $4K | – | – | – |
|
|
PMAM
7
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
| – | -$897K | -13,327 | Closed |
|
NRXP Hedge Fund Activity: Q3 2020 in Review
5 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q3 2020, worth a combined $2.16M — down 29% from $3.06M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of NRXP and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $721K. The largest seller was Bluefin Capital Management, exiting entirely with an estimated $946K sold.
- 5 institutional investors held NRX Pharmaceuticals (NRXP) as of Q3 2020, down from 6 in Q2 2020.
- Funds reported $2.16M of NRX Pharmaceuticals stock for Q3 2020, down 29% quarter-over-quarter.
- 1 fund opened new NRX Pharmaceuticals positions in Q3 2020 and 2 closed out, a net change of -1 holder.
- The largest NRX Pharmaceuticals buyer in Q3 2020 was Glazer Capital LLC, an estimated $721K added.
- The largest NRX Pharmaceuticals seller in Q3 2020 was Bluefin Capital Management, an estimated $946K sold.
Based on aggregated 13F filings for Q3 2020.